A. Stamatoullas

发表

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.

T. Molina, F. Bertucci, R. Bouabdallah, 2009, Blood.

Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy

F. Jardin, A. Stamatoullas, J. Picquenot, 2014, Leukemia & lymphoma.

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies

E. Clappier, A. Stamatoullas, J. Vial, 2018, British journal of haematology.

Eosinophilic leukemia associated with t(2;5)(p23;q31).

F. Jardin, A. Stamatoullas, S. Leprêtre, 2002, Cancer genetics and cytogenetics.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

A. Stamatoullas, M. Voso, R. Latagliata, 2017, The Lancet. Haematology.

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome

R. Margueron, A. Stamatoullas, M. Stern, 2019, Science Translational Medicine.

Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients

A. Stamatoullas, O. Casasnovas, J. Gabarre, 2013, Leukemia & lymphoma.

Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study

G. Salles, R. Bouabdallah, A. Stamatoullas, 2015 .

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

J. Raemaekers, R. Bouabdallah, A. Stamatoullas, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma

C. Copie-Bergman, T. Molina, F. Jardin, 2016, American journal of hematology.

Prognostic relevance of lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience

F. Jardin, A. Stamatoullas, H. Lanic, 2021, Leukemia & lymphoma.

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

A. Stamatoullas, J. Bennett, P. Fenaux, 2019, Leukemia research.

Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

J. Hernández-Rivas, A. Stamatoullas, P. Fenaux, 2018, British journal of haematology.

Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study

F. Jardin, A. Stamatoullas, H. Lanic, 2016, Leukemia & lymphoma.

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

A. Stamatoullas, A. Levis, P. Fenaux, 2013, Blood.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2012, Blood.

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

A. Stamatoullas, P. Fenaux, N. Vey, 2011, Leukemia research.

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

D. Swinkels, A. Stamatoullas, C. Craddock, 2020, Leukemia.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2011, Blood.

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

A. Stamatoullas, P. Fenaux, N. Vey, 2010, Leukemia research.

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

A. Stamatoullas, P. Morel, P. Fenaux, 2010, Leukemia research.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

H. Dombret, A. Stamatoullas, P. Greenberg, 2008, Blood.

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline

J. Raemaekers, A. Stamatoullas, P. Feugier, 2022, Haematologica.

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients

H. Dombret, A. Stamatoullas, P. Fenaux, 2014, Leukemia.

Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of myelodysplastic syndromes (MDS) on anemia, costs and quality of life: a randomized controlled trial.

A. Stamatoullas, A. Vekhoff, P. Durieux, 2004 .

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.

D. de Jong, E. Noordijk, A. Stamatoullas, 2017, International journal of radiation oncology, biology, physics.

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

A. Stamatoullas, M. Copin, O. Casasnovas, 2018, Haematologica.

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

R. Bouabdallah, A. Stamatoullas, S. Mareschal, 2016, Bone Marrow Transplantation.

Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant

A. Stamatoullas, O. Casasnovas, E. W. Van Den Neste, 2013, Haematologica.

Nodular, lymphocyte‐predominant Hodgkin lymphoma

B. Coiffier, A. Stamatoullas, V. Meignin, 2010, Cancer.

Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study

F. Jardin, A. Stamatoullas, J. Picquenot, 2019, Haematologica.

Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study

R. Bouabdallah, A. Stamatoullas, P. Feugier, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

R. Houot, A. Stamatoullas, O. Casasnovas, 2019, European journal of cancer.

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.

R. Houot, A. Stamatoullas, L. Dercle, 2018, Blood.

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

disease Waldenström macroglobulinemia in first relapse or with primary refractory of cyclophosphamide-doxorubicin-prednisone in 92 patients with Multicenter, randomized comparative trial of fludarabine and the combination

R. Porcher, A. Stamatoullas, E. Deconinck, 2013 .

Chromosome abnormalities in peripheral T-cell lymphoma.

A. Stamatoullas, S. Leprêtre, H. Tilly, 2000, Cancer genetics and cytogenetics.

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study

A. Stamatoullas, O. Casasnovas, N. Mounier, 2015, Haematologica.

All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

A. Stamatoullas, F. Morschhauser, P. Feugier, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

SUVmax-based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin’s lymphoma

F. Jardin, A. Stamatoullas, H. Tilly, 2020, Leukemia & lymphoma.

PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.

R. Bouabdallah, A. Stamatoullas, L. Fornecker, 2019, The Lancet. Oncology.

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

A. Stamatoullas, J. Tamburini, L. Fornecker, 2021, Haematologica.

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial

A. Stamatoullas, P. Feugier, M. Federico, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3′ BCL2 breakpoints and evidence of a new cluster

F. Jardin, A. Stamatoullas, S. Leprêtre, 2000, Leukemia.

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

A. Stamatoullas, S. Chevret, B. Quesnel, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

A. Stamatoullas, C. Elie, T. Lefèbvre, 2017, PloS one.

Conventional cytogenetics of nodular lymphocyte-predominant Hodgkin's lymphoma

P. Gaulard, A. Stamatoullas, J. Picquenot, 2007, Leukemia.

Successful treatment of severe post hematopoietic stem cell transplantation bronchiolitis obliterans syndrome with lung transplantation in a patient with multi‐organ chronic graft‐versus‐host disease

F. Jardin, J. Bourhis, A. Stamatoullas, 2022, Clinical Case Reports.

in MDS patients treated with AZA. Its prognostic value may be further improved by specific scoring systems established for AZA treatment such as the one we described previously.3

A. Stamatoullas, B. Quesnel, P. Fenaux, 2017 .

Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.

A. Stamatoullas, P. Fenaux, L. Adès, 2011, Leukemia research.

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5 q deletion : results of a phase 2 study

A. Stamatoullas, P. Fenaux, L. Adès, 2009 .

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

A. Stamatoullas, B. Quesnel, P. Fenaux, 2010, Haematologica.

A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM)

A. Stamatoullas, S. Chevret, P. Fenaux, 2013 .

Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

A. Stamatoullas, P. Fenaux, L. Adès, 2012, British journal of haematology.

Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)

H. Dombret, A. Stamatoullas, E. Wattel, 2010 .

Azacitidine for the treatment of relapsed and refractory AML in older patients.

H. Dombret, A. Stamatoullas, P. Fenaux, 2015, Leukemia research.

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

A. Stamatoullas, B. Quesnel, P. Fenaux, 2012 .

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

A. Stamatoullas, S. Chevret, E. Wattel, 2016, Haematologica.

Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study

A. Stamatoullas, P. Cony-Makhoul, E. Wattel, 2015 .

A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.

A. Stamatoullas, S. Chevret, P. Fenaux, 2013 .

Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM)

A. Stamatoullas, P. Cony-Makhoul, P. Fenaux, 2020, Transfusion.

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.

A. Stamatoullas, K. Götze, D. Steensma, 2020, Leukemia research.

Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)

H. Dombret, A. Stamatoullas, P. Fenaux, 2011 .

Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program

A. Stamatoullas, E. Solary, B. Quesnel, 2008 .

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.

H. Dombret, A. Stamatoullas, L. Mannone, 2008, Leukemia research.

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

A. Stamatoullas, A. Vekhoff, B. Quesnel, 2009, Leukemia research.

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

A. Stamatoullas, P. Fenaux, L. Adès, 2009, Leukemia.

Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program

A. Stamatoullas, B. Quesnel, E. Wattel, 2010 .

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

H. Dombret, A. Stamatoullas, B. Quesnel, 2009 .

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion

A. Stamatoullas, P. Fenaux, L. Adès, 2012, Genes, chromosomes & cancer.

59 Myelodysplastic syndromes with isolated neutropenia or thrombocytopenia: Are they refractory cytopenias with unilineage dysplasia? A GFM registry study

A. Stamatoullas, P. Fenaux, L. Adès, 2011 .

195 Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS)

A. Stamatoullas, E. Solary, P. Fenaux, 1997 .

Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial

P. Bartolomeo, A. Stamatoullas, R. Latagliata, 2015 .

P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study

A. Stamatoullas, P. Fenaux, J. Delaunay, 2013 .

Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM

A. Stamatoullas, B. Quesnel, P. Fenaux, 2008 .

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

A. Stamatoullas, S. Chevret, B. Quesnel, 2019, Blood.

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

H. Dombret, A. Stamatoullas, L. Mannone, 2006 .

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

A. Stamatoullas, P. Fenaux, L. Adès, 2005 .

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

A. Stamatoullas, G. Garcia-Manero, D. Steensma, 2014 .

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

A. Stamatoullas, P. Fenaux, L. Adès, 2007 .

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

A. Stamatoullas, S. Chevret, E. Wattel, 2019, Haematologica.

Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies

A. Stamatoullas, P. Fenaux, L. Adès, 2012 .

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

A. Stamatoullas, M. Federico, L. Specht, 2017 .

Secondary Philadelphia chromosome in a patient with acute lymphoblastic leukemia.

A. Stamatoullas, H. Tilly, C. Bastard, 2004, Cancer genetics and cytogenetics.

A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

A. Stamatoullas, S. Chevret, B. Quesnel, 2018, Blood.

Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

J. Raemaekers, R. Bouabdallah, A. Stamatoullas, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial

A. Stamatoullas, P. Moreau, E. Deconinck, 2010 .

Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

A. Stamatoullas, P. Feugier, M. André, 2022, Leukemia & lymphoma.

High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study.

A. Stamatoullas, M. Béné, P. Fenaux, 2009 .

Lactobacillus species as emerging pathogens in neutropenic patients

A. Stamatoullas, J. Lemeland, H. Tilly, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Hematological toxicity of ticlopidine

A. Stamatoullas, H. Tilly, F. Caron, 1994, American journal of hematology.

A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study

A. Stamatoullas, E. Wattel, P. Fenaux, 2010 .

Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group

H. Dombret, A. Stamatoullas, S. Chevret, 2010 .

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.

H. Dombret, A. Stamatoullas, E. Wattel, 2009 .

14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION

A. Stamatoullas, G. Garcia-Manero, D. Steensma, 2015 .

Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.

G. Salles, R. Bouabdallah, A. Stamatoullas, 2016 .

Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies

A. Fischer, A. Stamatoullas, I. Yakoub-Agha, 2005, Transplantation.

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

A. Stamatoullas, K. Götze, E. Solary, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q.

A. Stamatoullas, H. Tilly, C. Bastard, 1997, The American journal of surgical pathology.

Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.

A. Stamatoullas, B. Quesnel, L. Mannone, 2007 .

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

A. Stamatoullas, E. Wattel, P. Fenaux, 2004, The hematology journal : the official journal of the European Haematology Association.

Invasive Geotrichum clavatum Fungal Infection in an Acute Myeloid Leukaemia Patient: A Case Report and Review

F. Jardin, A. Stamatoullas, H. Lanic, 2014, Mycopathologia.

Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation.

A. Stamatoullas, H. Tilly, F. Proust, 1996, Bone marrow transplantation.

Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.

A. Stamatoullas, F. Morschhauser, P. Feugier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia

A. Stamatoullas, P. Rohrlich, N. Mounier, 2019, International Journal of Molecular Sciences.

Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics

F. Jardin, P. Gaulard, A. Stamatoullas, 2002, Leukemia.

De novo acute B cell leukemia/lymphoma with t(14;18)

P. Gaulard, A. Stamatoullas, S. Leprêtre, 2000, Leukemia.

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

H. Dombret, A. Stamatoullas, A. Delannoy, 2007, Leukemia.

Therapy in Newly Diagnosed Acute Promyelocytic Leukemia Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by

J. Miguel, H. Dombret, A. Stamatoullas, 2014 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

J. Miguel, H. Dombret, A. Stamatoullas, 2000 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

H. Dombret, A. Stamatoullas, E. Solary, 2000, British journal of haematology.

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, A. Stamatoullas, 1999, Blood.

Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study

F. Jardin, A. Stamatoullas, H. Tilly, 2022, Leukemia & lymphoma.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Lenalidomide with or without Erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5 q deletion Running title : Lenalidomide in transfused non del 5 q low risk MDS

Stanislas, Taksin, A. Stamatoullas, 2015 .

Prognostic value of chromosomal abnormalities in follicular lymphoma.

Annick, A. Stamatoullas, A. Rossi, 1994, Blood.

Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials.

J. Raemaekers, A. Stamatoullas, O. Casasnovas, 2018, Journal of cancer survivorship : research and practice.

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

H. Dombret, A. Stamatoullas, A. Delannoy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

A. Stamatoullas, P. Fenaux, L. Adès, 2009, Blood.

Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

F. Jardin, A. Stamatoullas, V. Ribrag, 2021, Human vaccines & immunotherapeutics.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group.

H. Dombret, A. Stamatoullas, A. Delannoy, 2007, Leukemia research.

Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.

A. Stamatoullas, A. Delannoy, C. Gardin, 2004, The Hematology Journal.

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

G. Salles, A. Stamatoullas, N. Brousse, 2001, Blood.

Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.

G. Salles, A. Stamatoullas, O. Casasnovas, 2009, Blood.

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.

G. Salles, F. Berger, A. Stamatoullas, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation

H. Dombret, A. Stamatoullas, A. Vekhoff, 2000, Leukemia.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

A. Stamatoullas, E. Solary, S. Chevret, 2016, Blood.

Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.

A. Stamatoullas, C. Bastard, C. Preudhomme, 2012 .

Human herpesvirus-6 acute limbic encephalitis after unrelated umbilical cord blood transplantation successfully treated with ganciclovir

F. Jardin, A. Stamatoullas, H. Lanic, 2015, Bone Marrow Transplantation.

Spontaneous remission in three cases of AML M5 with NPM1 mutation

F. Jardin, A. Stamatoullas, H. Lanic, 2015, Clinical case reports.

infection and outcome variations in the tumor microenvironment and correlations with EBV Molecular profiling of classical Hodgkin lymphoma tissues uncovers

T. Molina, F. Bertucci, D. Birnbaum, 2013 .

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

R. Bouabdallah, A. Stamatoullas, P. Feugier, 2019, The Lancet. Oncology.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

A. Stamatoullas, K. Götze, P. Cony-Makhoul, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma

F. Jardin, A. Stamatoullas, J. Picquenot, 2016, Leukemia & lymphoma.

Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas

F. Jardin, A. Stamatoullas, H. Lanic, 2021, Haematologica.

Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non‐Hodgkin's lymphoma

A. Stamatoullas, H. Tilly, C. Fruchart, 1996, Cancer.

Cyberlindnera jadinii (teleomorph Candida utilis) candidaemia in a patient with aplastic anaemia: a case report

F. Jardin, A. Stamatoullas, H. Lanic, 2018, JMM case reports.

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study

A. Stamatoullas, H. Tilly, H. Kluin-Nelemans, 2019, Health and Quality of Life Outcomes.

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

A. Stamatoullas, B. Quesnel, Q. Mo, 2021, Blood.

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.

R. Porcher, A. Stamatoullas, E. Deconinck, 2001, Blood.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

H. Dombret, A. Stamatoullas, S. Chevret, 2016, Haematologica.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

T. Molina, G. Salles, B. Coiffier, 2017, Haematologica.

¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.

F. Jardin, A. Stamatoullas, S. Leprêtre, 2015, Anticancer research.

Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first‐line treatment for patients with diffuse large B‐cell lymphoma

F. Jardin, A. Stamatoullas, H. Lanic, 2022, European journal of haematology.

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age

A. Stamatoullas, H. Tilly, C. Fruchart, 1997, Bone Marrow Transplantation.

Invasive Aspergillosis in Neutropenic Patients During Hospital Renovation: Effectiveness of Mechanical Preventive Measures in a Prospective Cohort of 438 Patients

F. Jardin, A. Stamatoullas, H. Lanic, 2015, Mycopathologia.

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.

H. Dombret, A. Stamatoullas, A. Vekhoff, 2004, Blood.

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

G. Salles, R. Bouabdallah, J. Jais, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

H. Dombret, A. Stamatoullas, E. Wattel, 2006, Haematologica.

Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma

Philippe Bertrand, Pierre Vera, Sylvain Mareschal, 2012, Leukemia & lymphoma.

Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.

J. Blay, G. Salles, A. Stamatoullas, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

A. Stamatoullas, G. Garcia-Manero, G. Borthakur, 2018, The Lancet. Haematology.

Invasive Geotrichum clavatum Fungal Infection in an Acute Myeloid Leukaemia Patient: A Case Report and Review

F. Jardin, A. Stamatoullas, H. Lanic, 2014, Mycopathologia.

Miescher cheilitis and myelomonocytic leukemia: a fortuitous association or a rare paraneoplastic syndrome?

F. Jardin, A. Stamatoullas, H. Tilly, 2010, Leukemia & lymphoma.

Multiple cutaneous ulcers revealing a primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

F. Jardin, A. Stamatoullas, H. Tilly, 2020, Clinical case reports.

Follicle center lymphoma is associated with significantly elevated levels of BCL-6 expression among lymphoma subtypes, independent of chromosome 3q27 rearrangements

F. Jardin, A. Stamatoullas, S. Leprêtre, 2002, Leukemia.

Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy

F. Jardin, A. Stamatoullas, J. Picquenot, 2014, European journal of haematology.

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort

F. Jardin, A. Stamatoullas, J. Picquenot, 2018, Blood Cancer Journal.

Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly

R. Bouabdallah, A. Stamatoullas, H. Lanic, 2015, British journal of haematology.

Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2007 .

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.

J. Blay, A. Stamatoullas, B. Quesnel, 2000, Haematologica.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin ' s lymphomas

A. Stamatoullas, B. Quesnel, C. Haioun, 2000 .

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

A. Stamatoullas, M. Béné, P. Fenaux, 2013, Annals of Hematology.

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma

F. Jardin, A. Stamatoullas, J. Picquenot, 2016, Haematologica.

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

A. Stamatoullas, T. Illidge, A. Gautam, 2018, British journal of haematology.

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

J. Cerhan, G. Salles, T. Habermann, 2013, Cytokine.

Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma

F. Jardin, A. Stamatoullas, J. Picquenot, 2018, Leukemia & lymphoma.

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA)

R. Houot, A. Stamatoullas, O. Casasnovas, 2022, British journal of haematology.

Thalidomide for the Treatment of Low Risk Myelodysplasia.

A. Stamatoullas, P. Fenaux, A. Aouba, 2004 .

TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm

F. Jardin, A. Stamatoullas, J. Picquenot, 2011, British journal of haematology.

[Intramedullary spinal cord metastasis and leptomeningeal involvement in Hodgkin's disease. Case report and review of the literature].

F. Jardin, A. Stamatoullas, H. Tilly, 1999, La Revue de medecine interne.

Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.

J. Raemaekers, B. Coiffier, A. Allgeier, 2014, Human reproduction.

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

A. Stamatoullas, S. Chevret, E. Wattel, 2016 .

Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B‐cell lymphoma, a clinico‐pathological series of 25 cases

C. Copie-Bergman, T. Molina, G. Salles, 2020, British journal of haematology.

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

A. Stamatoullas, V. Edeline, V. Ribrag, 2019, Blood.

Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report

F. Jardin, A. Stamatoullas, J. Picquenot, 2023, Clinical case reports.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

A. Stamatoullas, M. Robin, I. Yakoub-Agha, 2022, Bone Marrow Transplantation.

Arsenic Trioxide (AS2O3) Therapy for Relapsed Acute Promyelocytic Leukemia (APL): Comparison with a Historic Control Combining All-Trans Retinoic Acid (ATRA) Plus Intensive Chemotherapy.

A. Stamatoullas, M. Bernard, P. Fenaux, 2005 .

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

A. Stamatoullas, P. Fenaux, L. Adès, 2013, Leukemia.

Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials

J. Raemaekers, A. Stamatoullas, O. Casasnovas, 2023, Acta oncologica.

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort

F. Jardin, A. Stamatoullas, J. Picquenot, 2018, Blood Cancer Journal.

Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

C. Copie-Bergman, T. Molina, F. Jardin, 2015 .

Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

H. Dombret, A. Stamatoullas, A. Vekhoff, 2004 .

Short communication Secondary Philadelphia chromosome in a patient with acute lymphoblastic leukemia

A. Stamatoullas, C. Bastard, Lin Chen, 2004 .

Outcome of Treatment after First Relapse in Adults Patients with Acute Lymphoblastic Leukemia (ALL) Initially Treated by the LALA-94 Trial.

A. Stamatoullas, A. Delannoy, J. Gabert, 2006 .

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapy

F. Jardin, A. Stamatoullas, J. Picquenot, 2014, European journal of haematology.

Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly

R. Bouabdallah, A. Stamatoullas, H. Lanic, 2015, British journal of haematology.

Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM)

A. Stamatoullas, P. Cony-Makhoul, P. Fenaux, 2022, Transfusion.

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

H. Dombret, A. Stamatoullas, E. Wattel, 2006, Haematologica.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

A. Stamatoullas, E. Solary, S. Chevret, 2016, Blood.

Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program

R. Bouabdallah, A. Stamatoullas, M. Bernard, 2016, Haematologica.

Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study

A. Stamatoullas, H. Lanic, C. Fruchart, 2023, Annals of Hematology.